CN EN JP
{pboot:sort scode=} [sort:name]
[sort:name]
{/pboot:sort}
{pboot:sort scode=}[sort:name]{/pboot:sort}
2025.05.16Phase I Clinical Trial Officially Launched for CNS Drug ZHB601 for Injection
On May 15th, 2025, the Phase I clinical trial for ZHB601 for Injection - a Class I new chemical drug···
2025.05.05New Targeted Anti-Cancer Drug ZHB114 for Injection Granted New Indication Approval by U.S. FDA
On May 2nd, 2025, the Investigational New Drug (IND) application for ZHB114 for Injection—a Class I ···
2025.03.25Phase I Clinical Trial Application of Anti-Allergy Desensitization Drug ZHB117 Sublingual Tablets Approved by the NMPA
On March 24th, 2025, Zonhonbio's independently developed Class I new biologic drug—ZHB117 sublin···
2025.02.15Phase I Clinical Trial Officially Launched of Anti-Allergy Desensitization Drug ZHB110 Sublingual Tablets
On February 14th, 2025, the Phase I clinical trial for ZHB110 sublingual tablets—a Class 1 new biolo···
2025.01.27Phase I Clinical Trial Application of Central Nervous System Drug ZHB601 for Injection Approved by the NMPA
On January 26th, 2025, Zonhonbio's Class I new chemical drug—ZHB601 for Injection received the &···
2025.01.25The 2024 Annual Meeting and 2025 New Year Party os Zonhonbio and Gensunbio Held Successfully
Auspicious dragon ushers in achievement, and golden serpent welcomes a new journey. On January 22, 2···
2024.12.20Phase I Clinical Trial Application of Novel Targeted Anti-Cancer Drug ZHB015 for Injection Approved by the NMPA
On December 20, 2024, Zonhonbio's Class 1 innovative biological drug, ZHB015 for Injection, has ···
2024.11.04Phase I Clinical Trial of the Central Nervous System Drug ZHB103 Injection Officially Launched
On November 4th, 2024, Zonhonbio officially initiated the Phase I clinical trial of its wholly origi···